Literature DB >> 18789535

Assessment of Epstein-Barr virus (EBV) serostatus by enzyme immunoassays: plausibility of the isolated EBNA-1 IgG positive serological profile.

Tomás García1, Nuria Tormo, Concepción Gimeno, David Navarro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18789535     DOI： 10.1016/j.jinf.2008.07.017

Source DB:  PubMed          Journal:  J Infect        ISSN： 0163-4453            Impact factor:   6.072


× No keyword cloud information.
  5 in total

1.  Performance of two commercially available automated immunoassays for the determination of Epstein-Barr virus serological status.

Authors:  J Lupo; R Germi; T Semenova; M Buisson; J M Seigneurin; P Morand
Journal:  Clin Vaccine Immunol       Date:  2012-04-25

2.  Evaluation of the Architect Epstein-Barr Virus (EBV) viral capsid antigen (VCA) IgG, VCA IgM, and EBV nuclear antigen 1 IgG chemiluminescent immunoassays for detection of EBV antibodies and categorization of EBV infection status using immunofluorescence assays as the reference method.

Authors:  Isabel Corrales; Estela Giménez; David Navarro
Journal:  Clin Vaccine Immunol       Date:  2014-03-12

3.  Evaluation of four commercial systems for the diagnosis of Epstein-Barr virus primary infections.

Authors:  Fernando de Ory; María Eulalia Guisasola; Juan Carlos Sanz; Isabel García-Bermejo
Journal:  Clin Vaccine Immunol       Date:  2010-12-29

4.  Performance of new enzyme-linked fluorescent assays for detection of Epstein-Barr virus specific antibodies in routine diagnostics.

Authors:  Christoph Koidl; Regina Riedl; Bettina Schweighofer; Sandra Fett; Michael Bozic; Egon Marth
Journal:  Wien Klin Wochenschr       Date:  2011-03-31       Impact factor: 1.704

5.  Reliability of the Siemens Enzygnost and Novagnost Epstein-Barr virus assays for routine laboratory diagnosis: agreement with clinical diagnosis and comparison with the Merifluor Epstein-Barr virus immunofluorescence assay.

Authors:  Christina Kreuzer; Klaus Udo Nabeck; H Roma Levy; Elisabeth Daghofer
Journal:  BMC Infect Dis       Date:  2013-06-03       Impact factor: 3.090
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.